The first British patient was treated with an experimental drug for severe lung disease related to Covid-19, the University of Manchester’s NHS Foundation Trust said on Monday.
The patient is part of UK pharmaceutical giant GlaxoSmithKline PLC’s Oscar study to see if one of its pipeline drugs, otilimab, can help reduce the effects of what is known as the cytokine storm – a severe immune response the body starts to produce its own Attacking cells – which has been found in some hospitalized Covid-19 patients.
The drug is a monoclonal antibody that was in late-stage clinical trials and was originally seen as a potential new treatment for rheumatoid arthritis.
The patient will be treated at the Manchester Royal Infirmary, part of the University of Manchester̵
The Oscar study, which stands for otilimab in severe Covid-19 disease, is sponsored and funded by GlaxoSmithKline and is one of several studies that have received urgent public health research status from the UK Department of Health and Welfare .
The study is set to expand to more hospitals across the UK, said the University of Manchester’s NHS Foundation Trust.
Write to Adriano Marchese at [email protected]